REVIEW article
Front. Cardiovasc. Med.
Sec. Cardiovascular Imaging
This article is part of the Research TopicRevolutionizing Cardiovascular Diagnosis: Advances in Functional Imaging TechnologiesView all 14 articles
Cardiac Magnetic Resonance research advances in myocardial fibrosis of hypertrophic cardiomyopathy
Provisionally accepted
- 1Department of Radiology, Zigong First People's Hospital, Zigong, China
- 2Department of Ultrasound, Zigong Fourth People's Hospital, Zigong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Hypertrophic cardiomyopathy (HCM) is a common inherited myocardial disorder characterized by left ventricular wall thickening, cardiomyocyte disarray, and varying degrees of interstitial and replacement fibrosis. Myocardial fibrosis plays a central role in the pathological progression of HCM, directly contributing to ventricular remodeling, diastolic dysfunction, and electrical instability, and serves as a key mediator of adverse clinical outcomes such as arrhythmias, heart failure, and sudden cardiac death. In recent years, cardiac magnetic resonance imaging (CMR) has been widely adopted for the noninvasive detection and quantification of myocardial fibrosis in patients with HCM due to its high spatial resolution, multiparametric assessment capabilities, and excellent tissue specificity, demonstrating significant value in structural evaluation, risk stratification, and clinical decision-making. This review systematically summarizes the key research advances in recent years regarding the assessment of myocardial fibrosis in HCM using CMR, with a particular focus on the clinical applications and research frontiers of multiparametric imaging techniques such as late gadolinium enhancement (LGE), T1 mapping, and extracellular volume fraction (ECV) in fibrosis quantification, microstructural identification, and prognostic evaluation. Additionally, it explores the current challenges in imaging standardization, parameter stability, and multicenter validation, while also envisioning future development trends involving integration with artificial intelligence, multimodal imaging, and molecular biology in patients with HCM. The aim is to provide systematic academic references for mechanistic research and personalized management of HCM fibrosis.
Keywords: hypertrophic cardiomyopathy (HCM), Myocardial fibrosis, Cardiac magnetic resonance imaging (CMR), Late gadolinium enhancement (LGE), T1 Mapping, Extracellular Volume Fraction(ECV)
Received: 13 Aug 2025; Accepted: 04 Nov 2025.
Copyright: © 2025 Liu, Lv, Zhong and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yuan Li, 754115487@qq.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.